PERITONEAL CANCER

This phase 2 trial tests whether combining two oral drugs—ZEN003694 (a BET inhibitor) and talazoparib (a PARP inhibitor)—can shrink tumors in people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Participants must have already received a PARP inhibitor befo…

This early-stage trial is testing a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and to find the best dose. About 282 participants will receive…

This study is testing whether a combination of two drugs, mirvetuximab soravtansine and olaparib, can help keep ovarian, peritoneal, or fallopian tube cancer from coming back after initial treatment. About 53 women with cancer that responded to platinum-based chemotherapy will re…

This early-stage study tests a new experimental drug (NMS-03305293) combined with a standard chemotherapy (topotecan) in about 24 people whose ovarian cancer has returned after previous treatments. The main goals are to check safety and find the best dose, while also seeing if th…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This pilot study tests whether adding the blood thinner tinzaparin to standard chemotherapy can improve outcomes for women with advanced ovarian cancer. About 40 participants will receive either chemotherapy plus tinzaparin or chemotherapy alone. The main goal is to see if tinzap…

This early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. About 172 participants will receive differen…

This early-phase study is testing whether taking a daily 325 mg aspirin alongside standard chemotherapy can reduce immune-suppressing cells in ovarian, fallopian tube, or peritoneal tumors. About 100 women will take either aspirin or a placebo for up to 5 cycles of chemo. The goa…

This study tests a technique called acute normovolemic hemodilution (ANH) in 86 women having surgery for advanced ovarian cancer. Before surgery, some blood is removed and stored, then returned during or after the operation. The goal is to see if this reduces the need for donor b…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This Phase 3 trial is testing whether adding bevacizumab to niraparib after standard chemotherapy helps women with newly diagnosed advanced ovarian cancer stay cancer-free longer. About 970 participants will receive either niraparib alone or niraparib plus bevacizumab as maintena…

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…

This study collects tumor and blood samples from 3,300 people at high genetic risk for breast, ovarian, and related cancers. Researchers want to learn how these cancers develop and how well treatments work. Participants include those with BRCA1/2 or other gene mutations, or a str…

This early-stage study tests a small implantable device that is placed directly into tumors to see how different drugs work against ovarian, fallopian tube, and peritoneal cancers. About 20 people with advanced cancer will receive the device during standard surgery. The goal is t…

This study looks at 371 people with advanced ovarian, peritoneal, or fallopian tube cancer to find out what factors—like age, tumor type, and genetics—are linked to how long they live. Researchers will collect medical data and blood samples over two years. The goal is to build a …